Showing results (871-880 of 1,129) with videos related to
Sort By:
Pageof 113
Best Practice & Research. Clinical Haematology|August 26, 2003
FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitorsD Gary GillilandBest Practice & Research. Clinical Haematology|August 26, 2003
Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemiaMiguel A Sanz, Guillermo Martín, Francesco Lo CocoBest Practice & Research. Clinical Haematology|August 26, 2003
Retinoic acid syndrome: manifestations, pathogenesis, and treatmentRichard S Larson, Martin S TallmanBest Practice & Research. Clinical Haematology|August 26, 2003
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemiaAnna Falanga, Frederick R RicklesBest Practice & Research. Clinical Haematology|August 26, 2003
The importance of molecular monitoring in acute promyelocytic leukaemiaFrancesco Lo-Coco, Massimo Breccia, Daniela DiverioBest Practice & Research. Clinical Haematology|March 7, 2020
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!Dickran Kazandjian, Alexander Dew, Elizabeth HillBest Practice & Research. Clinical Haematology|March 7, 2020
Genomic profiling of multiple myeloma: New insights and modern technologiesMalin Hultcrantz, Venkata Yellapantula, Even H RustadBest Practice & Research. Clinical Haematology|March 7, 2020
CAR T and CAR NK cells in multiple myeloma: Expanding the targetsUrvi A Shah, Sham MailankodyBest Practice & Research. Clinical Haematology|November 30, 2019
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignanciesMathew L Cooper, John F DiPersioBest Practice & Research. Clinical Haematology|November 30, 2019
How advanced are we in targeting novel subtypes of ALL?Charles G MullighanPageof 113